Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients

Journal of Clinical Psychopharmacology

Volumn 18, Issue 4, 1998, Pages 311-316

  Carrillo, Juan A ^a   Herraiz, Angustias G ^b   Ramos, Sara I ^a   Benítez, Julio ^a  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b Psychiat Hosp Adolfo Diaz Ambrona   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CLOZAPINE; DRUG METABOLITE; NORCLOZAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIET; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG WITHDRAWAL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOTHESIS; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CAFFEINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLOZAPINE; CYTOCHROME P-450 CYP1A2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0031903147     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199808000-00011     Document Type: Article

References (39)

1. DeVane CL. Drug interactions and antipsychotic therapy. Pharmacotherapy 1996;16:15-20.
2. Carrillo JA, Benítez J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br J Clin Pharmacol 1996;41:605-8.
3. Haring C, Fleischhacker W, Schett P, Humpel C, Barnas C, Saria A. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry 1990;147:1471-5.
4. Meyer MC, Baldessarini RJ, Goff DC, Centorrino F. Clinically significant interactions of psychotropic agents with antipsychotic drugs. Drug Saf 1996;15:333-46.
5. Casey DE. What makes a neuroleptic atypical? In: Meltzer HY, ed. Novel antipsychotic drugs. New York: Raven Press, Ltd, 1992: 241-51.
6. Dahl ML, Bertilsson L. Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 1993; 3:61-70.
7. Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, Lindstrom L, Rodriguez de la Rubia I, Ramos S, Benítez J. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38:471-3.
8. Byerly MJ, DeVane CL. Pharmacokinetics of clozapine and risperidone: a review of recent literature. J Clin Psychopharmacol 1996;16:177-87.
9. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272:984-90.
10. Dain JG, Nicoletti J, Ballard F. Biotransformation of clozapine in humans. Drug Metab Dispos 1997;25:603-9.
11. Lemoine A, Gautier JC, Azoulay D, Kiffel L, Belloc C, Guengerich FP, Maurel P, Beaune P, Leroux JP. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993;43:827-32.
12. Nielsen KK, BrÌsen K, Hansen J, Gram LF. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994;55: 518-27.
13. Carrillo JA, Dahl ML, Svensson JO, Aim C, Rodríguez I, Bertilsson L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996;60:183-90.
14. Brøsen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45:1211-4.
15. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P-450 PA (P-450 1A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989;86:7696-700.
16. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, Swanson SP, Hamman MA, Wrighton SA. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996;276:658-66.
17. Hiemke C, Weigmann H, Härtter S, Dahmen N, Wetzel H, Müller H. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14:279-81.
18. Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994;16:368-74.
19. Vainer JL, Chouinard G. Interaction between caffeine and clozapine [letter]. J Clin Psychopharmacol 1994;14:284-5.
20. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993;53:503-14.
21. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996;6:121-49.
22. Carrillo JA, Benítez J. Caffeine metabolism in a healthy Spanish population: N-acetylator phenotype and oxidation pathways. Clin Pharmacol Ther 1994;55:293-304.
23. Overall JE, Gorham DR. Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812.
24. Lingjërde O, Ahlfors UG, Bech P, Dencker SJ, Eigen K. The UKU side effect rating scale. Acta Psychiatr Scand 1987;76:11-100.
25. Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. N Engl J Med 1991;324:746-54.
26. Collins EJ, Lalonde P, Jones BD, Addington D, MacCrimmon DJ, MacEwan GW, Teehan MD. Clozapine in the treatment of refractory schizophrenia: Canadian policies and clinical guidelines. Can J Psychiatry 1992;37:482-96.
27. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988;45:789-96.
28. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991;148:231-5.
29. Schwartz JT, Brotman AW. A clinical guide to antipsychotic drugs. Drugs 1992;44:981-92.
30. Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG. Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Psychopharmacol 1994;14:119-25.
31. McCarthy PT. Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry 1994;27:210-1.
32. Beale MD, Pritchett JT, Kellner CH. Supraventricular tachycardia in a patient receiving ECT, clozapine, and caffeine. Convuls Ther 1994;10:228-31.
33. Cohen LG, Chesley S, Eugenio L, Flood JG, Fisch J, Goff DC. Erythromycin-induced clozapine toxic reaction. Arch Intern Med 1996;156:675-7.
34. Funderburg LG, Vertrees JE, True JE, Miller AL. Seizure following addition of erythromycin to clozapine treatment[letter]. Am J Psychiatry 1994;151:1840-1.
35. Szymanski S, Lieberman JA, Picou D, Masiar S, Cooper T. A case report of cimetidine-induced clozapine toxicity. J Clin Psychiatry 1991;52:21-2.
36. Von Rosensteil NA, Adam D. Macrolide antibacterials. Drug interactions of clinical significance. Drug Saf 1995;13:105-22.
37. Idänpään-Heikkilä J, Alhava E, Olkinuora M, Palva IP. Agranulo-cytosis during treatment with clozapine. Eur J Clin Pharmacol 1977;11:193-8.
38. Haller E, Binder RL. Clozapine and seizures. Am J Psychiatry 1990;147:1069-71.
39. Littrell KH, Johnson CG, Schultz RE. The pharmacological management of clozapine-related seizures. J Psychosoc Nurs Ment Health Serv 1995;33:42-3.